Literature DB >> 21623630

Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives.

Francis Giraud1, Georges Alves, Eric Debiton, Lionel Nauton, Vincent Théry, Emilie Durieu, Yoan Ferandin, Olivier Lozach, Laurent Meijer, Fabrice Anizon, Elisabeth Pereira, Pascale Moreau.   

Abstract

The synthesis of new meridianin derivatives is described. The indolic ring system was substituted at the C-4 to C-7 positions either by a bromine atom or by nitro or amino groups. Additionally, an iodine atom or various aryl groups were introduced at the C-5 position of the 2-aminopyrimidine ring. These compounds as well as some of their synthetic intermediates were tested for their kinase inhibitory potencies and for their in vitro antiproliferative activities. We found that this series of compounds is particularly interesting in the development of new inhibitors of DYRK1A and CLK1 kinases. The most effective compounds toward these two kinase families are the 6- and 7-bromo derivatives 30, 33, and 34 that showed more than 45-fold selectivity toward DYRK1A/CLK1 kinases over the other kinases tested. Meridianin derivatives could thus be developed toward potent and selective inhibitors of key RNA splicing regulators and potential therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623630     DOI: 10.1021/jm200464w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  Natural products as inspiration for the development of bacterial antibiofilm agents.

Authors:  Roberta J Melander; Akash K Basak; Christian Melander
Journal:  Nat Prod Rep       Date:  2020-07-01       Impact factor: 13.423

2.  Meridianin D Analogues Display Antibiofilm Activity against MRSA and Increase Colistin Efficacy in Gram-Negative Bacteria.

Authors:  William M Huggins; William T Barker; James T Baker; Nicholas A Hahn; Roberta J Melander; Christian Melander
Journal:  ACS Med Chem Lett       Date:  2018-05-25       Impact factor: 4.345

3.  Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Roberto Sanchez; Ethan A Swartz; Andrew F Stewart; Robert J DeVita
Journal:  J Med Chem       Date:  2018-08-21       Impact factor: 7.446

4.  Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

Authors:  Kunal Kumar; Peter Man-Un Ung; Peng Wang; Hui Wang; Hailing Li; Mary K Andrews; Andrew F Stewart; Avner Schlessinger; Robert J DeVita
Journal:  Eur J Med Chem       Date:  2018-08-22       Impact factor: 6.514

Review 5.  Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.

Authors:  Akanksha Kulshreshtha; Poonam Piplani
Journal:  Neurol Sci       Date:  2016-06-01       Impact factor: 3.307

Review 6.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

Review 7.  Evaluation of small molecule kinase inhibitors as novel antimicrobial and antibiofilm agents.

Authors:  Ashley King; Meghan S Blackledge
Journal:  Chem Biol Drug Des       Date:  2021-10-04       Impact factor: 2.817

8.  2-(4-Bromo-1H-indol-3-yl)acetonitrile.

Authors:  Qiu-Xia Mao; Chen-Guang Zhang; Jin-Feng Li
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-01-18

9.  10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.

Authors:  Hannes Falke; Apirat Chaikuad; Anja Becker; Nadège Loaëc; Olivier Lozach; Samira Abu Jhaisha; Walter Becker; Peter G Jones; Lutz Preu; Knut Baumann; Stefan Knapp; Laurent Meijer; Conrad Kunick
Journal:  J Med Chem       Date:  2015-03-23       Impact factor: 7.446

10.  Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

Authors:  Kunal Kumar; Peng Wang; Jessica Wilson; Viktor Zlatanic; Cecilia Berrouet; Susmita Khamrui; Cody Secor; Ethan A Swartz; Michael Lazarus; Roberto Sanchez; Andrew F Stewart; Adolfo Garcia-Ocana; Robert J DeVita
Journal:  J Med Chem       Date:  2020-02-19       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.